Showing results (1791-1800 of 3,353) with videos related to
Sort By:
Pageof 336
Pharmacoeconomics|November 3, 1997
Application of the findings of the European Stroke Prevention Study 2 (ESPS-2) to a New Zealand ischaemic stroke cost analysisG Scott, H M ScottPharmacoeconomics|November 3, 1997
Measuring patient benefit from botulinum toxin in the treatment of dystonia. Feasibility of cost-utility analysisC M Gudex, M R Hawthorne, A G Butler, et al.Pharmacoeconomics|December 8, 1997
Cost effectiveness of a low-molecular-weight heparin in prolonged prophylaxis against deep vein thrombosis after total hip replacementB Detournay, A Planes, N Vochelle, et al.Pharmacoeconomics|December 8, 1997
Economic evaluation of desirudin vs heparin in deep vein thrombosis prevention after hip replacement surgeryL A Levin, M Horst, D BergqvistPharmacoeconomics|December 8, 1997
The effect of changes in treatment patterns on drug expenditureU G Gerdtham, M Johannesson, B Gunnarsson, et al.Pharmacoeconomics|April 7, 1998
Fluoxetine. A pharmacoeconomic review of its use in depressionM I Wilde, P BenfieldPharmacoeconomics|August 5, 1998
Outcomes of pharmacological and surgical treatment for obesityJ Cerulli, M MalonePharmacoeconomics|August 5, 1998
The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysisR C Dodel, M Singer, R Köhne-Volland, et al.Pharmacoeconomics|December 8, 1997
Managed care in Germany and Switzerland. Two approaches to a common problemP ZweifelPageof 336